Prime Medicine (NASDAQ:PRME) Hits New 1-Year High - Time to Buy?

Key Points

• Prime Medicine's stock reached a new 52-week high of $5.63, closing at $5.54 with a trading volume of 3.23 million shares.
• Wall Street Zen downgraded Prime Medicine's rating from "hold" to "sell" on September 2nd.
• The company's market capitalization stands at $745.52 million with a PE ratio of -3.55 and a beta of 2.38.

Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $5.63 and last traded at $5.54, with a volume of 3228599 shares trading hands. The stock had previously closed at $5.32.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Prime Medicine from a "hold" rating to a "sell" rating in a research note on Tuesday, September 2nd.

Prime Medicine Trading Up 4.1%

The stock has a market capitalization of $745.52 million, a PE ratio of -3.55 and a beta of 2.38.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.